August 7, 2007 in Nation/World

FDA approves new HIV medicine

Lauran Neergaard Associated Press
 

WASHINGTON – The government approved a novel drug Monday to help patients with the AIDS virus who are running out of options, while acknowledging lingering questions about the pills’ long-term effects.

Pfizer Inc.’s Selzentry is the first anti-AIDS drug that works by blocking a crucial doorway, called the CCR5 receptor, that the HIV virus often uses to enter white blood cells.

New York-based Pfizer said the pill, known chemically as maraviroc, would be available next month. A spokeswoman said it would cost about the same as other HIV medicines, roughly $900 a month wholesale.

It marks the first in a new class of HIV medicines since 2003, when the FDA approved an injectable “fusion inhibitor” that blocks a slightly later stage of infection.

The Food and Drug Administration approved Selzentry after concluding that certain hard-to-treat patients need the new option – but is requiring Pfizer to conduct further research to assess long-term side effects, said Dr. Debra Birnkrant, the agency’s HIV drugs chief.

The drug is not for the newly diagnosed, but only for patients whose virus is fast becoming resistant to today’s HIV drugs, she stressed.

Patients determined to have so-called “R5 virus” would take the twice-a-day pill in addition to their usual HIV drugs.

In a six-month study where patients added either Selzentry or a dummy pill to their regular medicine, Selzentry users were twice as likely to have their virus levels become almost unmeasurable, she said.

Topping the side-effect list is a stern warning that the drug may damage the liver, with symptoms that may at first mimic an allergic reaction. People who develop signs of hepatitis or an allergic reaction should see a doctor immediately.

Pfizer also warned that studies counted more cardiovascular problems, including heart attacks, in Selzentry users. Other side effects include dizziness, upper respiratory infections and fever.

© Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Get stories like this in a free daily email


Please keep it civil. Don't post comments that are obscene, defamatory, threatening, off-topic, an infringement of copyright or an invasion of privacy. Read our forum standards and community guidelines.

You must be logged in to post comments. Please log in here or click the comment box below for options.

comments powered by Disqus